Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea
· Delayed Price · Currency is KRW 4,940.00
+60.00 (1.23%)
At close: Apr 29, 2026
Jin Yang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 120,686 | 113,332 | 94,111 | 76,264 | 62,839 | Upgrade
|
| Other Revenue | - | -0 | - | -0 | - | Upgrade
|
| Revenue | 120,686 | 113,332 | 94,111 | 76,264 | 62,839 | Upgrade
|
| Revenue Growth (YoY) | 6.49% | 20.42% | 23.40% | 21.36% | 26.88% | Upgrade
|
| Cost of Revenue | 42,535 | 43,448 | 36,652 | 30,613 | 28,856 | Upgrade
|
| Gross Profit | 78,151 | 69,884 | 57,459 | 45,651 | 33,984 | Upgrade
|
| Selling, General & Admin | 72,891 | 59,052 | 46,381 | 33,981 | 27,965 | Upgrade
|
| Other Operating Expenses | 657.35 | 205.11 | 170.02 | 139.73 | 146.93 | Upgrade
|
| Operating Expenses | 75,625 | 58,175 | 48,374 | 34,513 | 27,020 | Upgrade
|
| Operating Income | 2,526 | 11,708 | 9,085 | 11,138 | 6,964 | Upgrade
|
| Interest Expense | -2,292 | -1,855 | -1,374 | -1,285 | -208.28 | Upgrade
|
| Interest & Investment Income | 41.68 | 481.5 | 1,472 | 356.59 | 16.99 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.41 | -2.38 | -1.69 | 3.53 | -0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,093 | 2,439 | 937.36 | 839.11 | 3,913 | Upgrade
|
| EBT Excluding Unusual Items | -818.66 | 12,771 | 10,119 | 11,053 | 10,685 | Upgrade
|
| Gain (Loss) on Sale of Investments | 28,888 | 24,298 | 2,253 | 3,132 | 1,438 | Upgrade
|
| Gain (Loss) on Sale of Assets | 31.33 | -77.14 | 0.86 | 24.9 | 9.53 | Upgrade
|
| Asset Writedown | - | - | - | 325.53 | - | Upgrade
|
| Other Unusual Items | - | 62.21 | 210.2 | - | - | Upgrade
|
| Pretax Income | 28,101 | 37,054 | 12,583 | 14,535 | 12,132 | Upgrade
|
| Income Tax Expense | 5,814 | 7,360 | -75.78 | 2,227 | 2,594 | Upgrade
|
| Net Income | 22,287 | 29,694 | 12,659 | 12,308 | 9,538 | Upgrade
|
| Net Income to Common | 22,287 | 29,694 | 12,659 | 12,308 | 9,538 | Upgrade
|
| Net Income Growth | -24.95% | 134.57% | 2.85% | 29.05% | 82.41% | Upgrade
|
| Shares Outstanding (Basic) | - | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | - | 12 | 12 | 13 | 11 | Upgrade
|
| Shares Change (YoY) | - | -1.17% | -7.18% | 17.77% | 2.12% | Upgrade
|
| EPS (Basic) | - | 2692.30 | 1174.67 | 1114.86 | 853.30 | Upgrade
|
| EPS (Diluted) | - | 2408.01 | 1014.53 | 915.61 | 835.60 | Upgrade
|
| EPS Growth | - | 137.35% | 10.80% | 9.57% | 78.63% | Upgrade
|
| Free Cash Flow | -2,801 | -77,268 | 7,851 | 4,230 | -545.86 | Upgrade
|
| Free Cash Flow Per Share | - | -6265.96 | 629.22 | 314.65 | -47.82 | Upgrade
|
| Gross Margin | 64.76% | 61.66% | 61.06% | 59.86% | 54.08% | Upgrade
|
| Operating Margin | 2.09% | 10.33% | 9.65% | 14.61% | 11.08% | Upgrade
|
| Profit Margin | 18.47% | 26.20% | 13.45% | 16.14% | 15.18% | Upgrade
|
| Free Cash Flow Margin | -2.32% | -68.18% | 8.34% | 5.55% | -0.87% | Upgrade
|
| EBITDA | 4,935 | 13,733 | 11,740 | 13,429 | 9,117 | Upgrade
|
| EBITDA Margin | 4.09% | 12.12% | 12.47% | 17.61% | 14.51% | Upgrade
|
| D&A For EBITDA | 2,409 | 2,024 | 2,655 | 2,291 | 2,154 | Upgrade
|
| EBIT | 2,526 | 11,708 | 9,085 | 11,138 | 6,964 | Upgrade
|
| EBIT Margin | 2.09% | 10.33% | 9.65% | 14.61% | 11.08% | Upgrade
|
| Effective Tax Rate | 20.69% | 19.86% | - | 15.32% | 21.38% | Upgrade
|
| Advertising Expenses | 3,268 | 3,748 | 3,869 | 2,541 | 2,125 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.